4502 Takeda Pharmaceutical
- 4130.0
- -8.0-0.19%
Takeda Pharmaceutical News
Takeda Canada Completes LOI Stage for Post-Transplant Cytomegalovirus Treatment
Takeda Pharmaceutical's (TAK) Canada unit said Thursday it has completed talks with the pan-Canadian Pharmaceutical Alliance for a letter of intent to provide public access to Livtencity as a treatmen
Takeda Canada Inc. Concludes Letter of Intent (LOI) With the Pan-Canadian Pharmaceutical Alliance (PCPA) for LIVTENCITY (Maribavir) for the Treatment of Adults With a Post-Transplant Cytomegalovirus (CMV) Infection
Takeda Canada Inc. ("Takeda") is pleased to announce that it has completed negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) for a Letter of Intent (LOI) for LIVTENCITY (maribavir) for
Express News | Takeda's dengue vaccine is pre-qualified by WHO
Takeda Pharmaceutical's Dengue Vaccine Granted WHO Prequalification
Takeda Pharmaceutical's (TAK) dengue vaccine TAK-003 received prequalification from the World Health Organization on Friday, the WHO said Wednesday. TAK-003, a vaccine containing weakened forms of fou
Takeda (TAK.US) TYK2 inhibitors launch psoriatic phase 3 clinical global program in China to recruit 1,600 people
Recently, the China Drug Clinical Trial Registration and Information Disclosure Platform announced that Takeda (TAK.US) has initiated two international multi-center (including China) phase 3 clinical studies of TAK-279 tablets, targeting moderate to severe plaque psoriasis.
Express News | Who- Tak-003 Is Second Dengue Vaccine to Be Prequalified by Who
Convertible Stock List (Part 1) [Parabolic Signal Convertible Stock List]
○List of trading stocks market code stock name closing price SAR Tokyo Stock Exchange Prime ＜1332＞ Nissui 920 873 ＜1605＞ INPEX 2390 2306 ＜1662＞ petroleum resources 6760 6530 ＜1802＞ Obayashi Gumi 1901 1668 ＜1870＞ Yahagi Ken
Scilex Holding Says Federal Court Approved Settlement With Takeda Pharmaceutical in Gloperba Patent Dispute
Express News | Takeda Pharmaceuticals' fiscal year 2023 revenue increased 5.9% year over year
The Nikkei Average in the backstage started with a depreciation of 69 yen, and Chugai Yakuhin, Mitsui, etc. fell
[Nikkei Stock Average, TOPIX (table)] Nikkei Average; 38109.66; -69.80 TOPIX; 2716.38; -7.70 [Backward Closer Overview] The backward Nikkei Average started at 38109.66 yen, 69.80 yen lower than the previous day, and turned downward from the previous draw (38199.10 yen). Nikkei 225 futures during lunchtime fell in the range of 38100 yen to 38220 yen. The dollar and yen depreciated by 20 yen from around 9:00 a.m., and the dollar was at a high level of 1 dollar = 156.40-50 yen. A
Nikkei Average Contribution Ranking (advance closing) ~ The Nikkei Average rebounded slightly, and Advantest boosted by about 33 yen with 1 brand
The number of gains and falls of the Nikkei Average constituent stocks as of closing 14 days ago was 102 stocks with price increases, 123 stocks with price drops, and 0 stocks unchanged. The Nikkei Average rebounded slightly. The front-end transaction was closed at 38199.10 yen (estimated turnover of 990 million shares), 19.64 yen higher (+0.05%) compared to the previous day. The US stock market on the 13th was mixed. The Dow average depreciated by $81.33 (-0.21%) to $39431.51, and the Nasdaq rose 47.37 points (+ 0.29%) to 16388
Express News | Takeda Pharmaceuticals Reaches Alzheimer's Disease Vaccine Development Agreement
Sector Update: Health Care Stocks Mixed Late Afternoon
Health care stocks were mixed in late Monday afternoon trading with the NYSE Health Care Index up 0.1% and the Health Care Select Sector SPDR Fund (XLV) decreasing 0.2%. The iShares Biotechnology ETF
Sector Update: Health Care
Health care stocks were mixed late Monday afternoon with the NYSE Health Care Index up 0.1% and the Health Care Select Sector SPDR Fund (XLV) decreasing 0.2%. The iShares Biotechnology ETF (IBB) added
Alzheimer's vaccine concept stocks rose more than 30% to finalize more than $2 billion agreement with pharmaceutical giants
① Similar to previous infusion therapy, the AC Immune vaccine is designed to produce antibodies against beta-amyloid; ② However, compared to infusion treatment, the vaccine can greatly reduce the number of treatments required; ③ According to the progress of ACI-24.060, there are still several years to go until regulatory approval.
AC Immune Enters Licensing Deal for Alzheimer's Disease Drug Candidate
AC Immune SA (IMR.F) said Monday it signed an exclusive option and license agreement with Japan's Takeda Pharmaceutical (TKD.F) for the former's ACI-24.060, a potential Alzheimer's disease drug treatm
AC Immune Rockets 47% on Alzheimer's Therapy Deal With Takeda
Wall Street Set to Open Higher Monday as Investors Look Toward Key Inflation Figures
US stocks look set to open modestly higher in Monday's trading session as investors await key inflation data coming out during the week. Dow Jones Industrial Average futures were up 0.3%, S&P 500 futu
Takeda Pharmaceuticals (TAK.US) introduces AC Immune Alzheimer's Abeta vaccine therapy
On May 13, Takeda Pharmaceuticals (TAK.US) announced the introduction of AC Immune's Alzheimer's Abeta vaccine therapy ACI-24.060.
Alzheimer's Vaccine Licensing Deal Boosts AC Immune
By Eleanor Laise Stock jumps more than 50% on agreement that will help move experimental vaccine into late-stage trials AC Immune S.A. shares (ACIU) jumped more than 50% premarket on Monday after th
Analysis
Price Target
No Data
